Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.
Abraham J, Prajapati SI, Nishijo K, Schaffer BS, Taniguchi E, Kilcoyne A, McCleish AT, Nelon LD, Giles FG, Efstratiadis A, LeGallo RD, Nowak BM, Rubin BP, Malempati S, Keller C. Abraham J, et al. Among authors: malempati s. Mol Cancer Ther. 2011 Apr;10(4):697-707. doi: 10.1158/1535-7163.MCT-10-0695. Epub 2011 Mar 29. Mol Cancer Ther. 2011. PMID: 21447712 Free PMC article.
Overcoming autopsy barriers in pediatric cancer research.
Alabran JL, Hooper JE, Hill M, Smith SE, Spady KK, Davis LE, Peterson LS, Malempati S, Ryan CW, Acosta R, Spunt SL, Keller C. Alabran JL, et al. Among authors: malempati s. Pediatr Blood Cancer. 2013 Feb;60(2):204-9. doi: 10.1002/pbc.24320. Epub 2012 Sep 26. Pediatr Blood Cancer. 2013. PMID: 23015377 Free PMC article.
The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Malempati S, Weigel BJ, Chi YY, Tian J, Anderson JR, Parham DM, Teot LA, Rodeberg DA, Yock TI, Shulkin BL, Spunt SL, Meyer WH, Hawkins DS. Malempati S, et al. Cancer. 2019 Jan 15;125(2):290-297. doi: 10.1002/cncr.31770. Epub 2018 Oct 23. Cancer. 2019. PMID: 30351457 Free PMC article. Clinical Trial.
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.
Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, Krailo M, Villaluna D, Adamson PC, Blaney SM. Weigel B, et al. Among authors: malempati s. Pediatr Blood Cancer. 2014 Mar;61(3):452-6. doi: 10.1002/pbc.24605. Epub 2013 Aug 17. Pediatr Blood Cancer. 2014. PMID: 23956055 Free PMC article. Clinical Trial.
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.
Kopp LM, Malempati S, Krailo M, Gao Y, Buxton A, Weigel BJ, Hawthorne T, Crowley E, Moscow JA, Reid JM, Villalobos V, Randall RL, Gorlick R, Janeway KA. Kopp LM, et al. Among authors: malempati s. Eur J Cancer. 2019 Nov;121:177-183. doi: 10.1016/j.ejca.2019.08.015. Epub 2019 Oct 3. Eur J Cancer. 2019. PMID: 31586757 Free PMC article. Clinical Trial.
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.
Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Reid JM, Schmechel S, Voss SD, Cho SY, Chen HX, Krailo MD, Adamson PC, Blaney SM. Malempati S, et al. J Clin Oncol. 2012 Jan 20;30(3):256-62. doi: 10.1200/JCO.2011.37.4355. Epub 2011 Dec 19. J Clin Oncol. 2012. PMID: 22184397 Free PMC article. Clinical Trial.
37 results